1/19
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai |
|---|
No analytics yet
Send a link to your students to track their progress
HLA-B*57:01
Abacavir hypersensitivity
CYP2B6*6
Efavirenz toxicity
UGT1A1*28
Atazanavir hyperbilirubinemia
ABCB1 3435C>T
Increased HAART failure
CCR5-Δ32
HIV resistance
CYP2C19*2/*3
Poor clopidogrel activation
CES1 G143E
Increased active clopidogrel metabolite
PON1 192Q
Worse cardiovascular outcomes
CYP4F2*3
Higher warfarin dose
CYP2C9 rs12777823
Warfarin dosing in African ancestry
CES1 rs2244613
Reduced dabigatran bleeding
APOE4
Increased AD risk, poorer response
APOE2
Protective
CHAT -5293 T
Better donepezil response
Ala539Thr
Slower cognitive decline
PSEN2 N141I
Increased COX-2 expression
DRD3 Ser/Ser
Better pramipexole response
CYP4F2 *tt*
Associated with increased Ticagrelor exposure/bleeding
PTGS1 C50T
Associated with ASA resistance
HLA-DPB1
Associated with ASA induced asthma